Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24043223 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Michel Boutin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche-CIUSSS de l'Estrie-CHUS, Univers…. Hauptthemen laut MEDLINE: Glycolipids, Fabry Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Funds from C. Auray-Blais, Sanofi Genzyme, C. Auray-Blais.
Abstract (Originalsprache)
Fabry disease (FD) is an X-linked lysosomal storage disorder where impaired α-galactosidase A enzyme activity leads to the intracellular accumulation of undegraded glycosphingolipids, including globotriaosylsphingosine (lyso-Gb3) and related analogues. Lyso-Gb3 and related analogues are useful biomarkers for screening and should be routinely monitored for longitudinal patient evaluation. In recent years, a growing interest has emerged in the analysis of FD biomarkers in dried blood spots (DBSs), considering the several advantages compared to venipuncture as a technique for collecting whole-blood specimens. The focus of this study was to devise and validate a UHPLC-MS/MS method for the analysis of lyso-Gb3 and related analogues in DBSs to facilitate sample collection and shipment to reference laboratories. The assay was devised in conventional DBS collection cards and in Capitainer®B blood collection devices using both capillary and venous blood specimens from 12 healthy controls and 20 patients affected with FD. The measured biomarker concentrations were similar in capillary and venous blood specimens. The hematocrit (Hct) did not affect the correlation between plasma and DBS measurements in our cohort (Hct range: 34.3–52.2%). This UHPLC-MS/MS method using DBS would facilitate high-risk screening and the follow-up and monitoring of patients affected with FD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Genetics, Department of Pediatrics, Faculty of Medicine and Health Sciences, Centre de Recherche-CIUSSS de l'Estrie-CHUS, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
- Institut de Pharmacologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
- Research Center, Hôpital du Sacré-Coeur de Montreal, University of Montreal and Nephrology Service, Montreal, QC H4J 1C5, Canada.
ORCID-Profile: Michel Boutin
Förderung
- Funds from C. Auray-Blais
- Sanofi Genzyme
- C. Auray-Blais
Zitieren
APA
Boutin, M., Lavoie, P., Beaudon, M., Kabala Ntumba, G., Bichet, D. G., Maranda, B., & Auray-Blais, C. (2023). Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043223
Vancouver
Boutin M, Lavoie P, Beaudon M, Kabala Ntumba G, Bichet DG, Maranda B, et al. Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043223
BibTeX
@article{Boutin2023,
author = {Boutin, Michel and Lavoie, Pamela and Beaudon, Margot and Kabala Ntumba, Georges and Bichet, Daniel G and Maranda, Bruno and Auray-Blais, Christiane},
title = {Mass Spectrometry Analysis of Globotriaosylsphingosine and Its Analogues in Dried Blood Spots},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24043223}
}
EUVIMED